

**LISTING OF CLAIMS:**

1. (Previously presented) A method of treating a condition related to resistance to cell death, comprising administering to a patient a pharmaceutical composition comprising a cupredoxin, to promote cell death in a cell demonstrating resistance to cell death.
2. (Previously presented) The method of claim 1, wherein the cupredoxin binds to tumor-suppressor protein p53.
3. (Previously presented) The method of claim 1, wherein the cupredoxin is selected from the group consisting of an azurin, a pseudoazurin, a plastocyanin, and a rusticyanin.
4. (Previously presented) The method of claim 3, wherein the cupredoxin is an azurin.
5. (Previously presented) The method of claim 4, wherein the cupredoxin is an azurin comprising the amino acid sequence of SEQ ID NO: 1, a mutant azurin or a truncated azurin.
6. (Previously presented) The method of claim 5, wherein the cupredoxin binds a tumor-suppressor protein p53.
7. (Previously presented) The method of claim 4, wherein the azurin comprises the amino acid sequence of SEQ ID NO: 6.
8. (Previously presented) The method of claim 4, wherein the azurin comprises the amino acid sequence of SEQ ID NO: 7.
9. (Previously presented) The method of claim 3, wherein the cupredoxin is a plastocyanin.
10. (Previously presented) The method of claim 9, wherein the cupredoxin is a plastocyanin comprising the amino acid sequence of SEQ ID NO: 2, a mutant plastocyanin or a truncated plastocyanin.
11. (Withdrawn) The method of claim 3, wherein the cupredoxin is a pseudoazurin.
12. (Withdrawn) The method of claim 11, wherein the cupredoxin is a pseudoazurin comprising the amino acid sequence of SEQ ID NO: 4, or an amino acid